{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:33:18Z","timestamp":1773131598424,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.autrev.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T23:48:59Z","timestamp":1509752939000},"page":"11-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate"],"prefix":"10.1016","volume":"17","author":[{"given":"Gabriella","family":"Moroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Raffiotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Binda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Lightstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios T.","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.11.003_bb0005","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2010.135186","article-title":"Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0010","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.11.003_bb0015","first-page":"1265","article-title":"Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0020","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/art.38006","article-title":"Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus","volume":"65","author":"Mok","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/rheumatology\/kep012","article-title":"Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort","volume":"48","author":"Danila","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.11.003_bb0030","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1970 to 2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.24545","article-title":"Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population","volume":"61","author":"Li","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.11.003_bb0040","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1002\/art.34672","article-title":"Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.11.003_bb0050","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.ki.5001722","article-title":"Treatment of proliferative lupus nephritis: a changing landscape","volume":"70","author":"Adu","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2017.11.003_bb0055","first-page":"1563","article-title":"Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure","volume":"33","author":"Faurschou","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0060","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2017.11.003_bb0065","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/art.39674","article-title":"Longitudinal analysis of outcomes of lupus nephritis in an international inception cohort using a multistate model approach","volume":"68","author":"Hanly","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0070","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/0961203316673728","article-title":"Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort","volume":"26","author":"Riveros Frutos","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0075","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0961203313492576","article-title":"Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20years","volume":"22","author":"Moroni","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0080","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0085","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0090","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U","article-title":"Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0100","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2017.11.003_bb0105","first-page":"i114","article-title":"It hasn't gone away: the problem of glucocorticoid use in lupus remains","volume":"56","author":"Apostolopoulos","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.11.003_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1445-5994.2006.01044.x","article-title":"Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus","volume":"36","author":"Lee","year":"2006","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2017.11.003_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/art.23352","article-title":"Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?","volume":"59","author":"Karp","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14656566.2016.1276563","article-title":"Synthetic pharmacotherapy for lupus nephritis","volume":"18","author":"Moroni","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2017.11.003_bb0125","article-title":"Azathioprine for multiple sclerosis","volume":"4","author":"Casetta","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.11.003_bb0130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/0961203309356292","article-title":"Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis","volume":"19","author":"Walsh","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0135","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00005792-199603000-00005","article-title":"Remission of systematic lupus erythematosus","volume":"75","author":"Drenkard","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.11.003_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.md.0000104742.42401.e2","article-title":"The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among \u201cHispanics\u201d","volume":"83","author":"Pons-Estel","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.11.003_bb0145","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.131137","article-title":"Prolonged clinical remission in patients with systemic lupus erythematosus","volume":"41","author":"Steiman","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0150","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0155","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/03009749409103047","article-title":"Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal","volume":"23","author":"Pablos","year":"1994","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1191\/096120301680416931","article-title":"Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis","volume":"10","author":"Mosca","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0165","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/art.1780371212","article-title":"Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide","volume":"37","author":"Euler","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40697-014-0030-9","article-title":"The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial","volume":"1","author":"Galbraith","year":"2014","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/0961203317694257","article-title":"Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis","author":"Park","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0180","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2017.11.003_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang-A-Sjoe","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.11.003_bb0190","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM197205252862116","article-title":"Exacerbation of SLE nephritis after cyclophosphamide withdrawal","volume":"286","author":"Aptekar","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.003_bb0195","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/ndt\/gfl208","article-title":"Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible?","volume":"21","author":"Grootscholten","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2017.11.003_bb0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9343(88)80366-8","article-title":"Discontinuation of therapy in diffuse proliferative lupus nephritis","volume":"85","author":"Ponticelli","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2017.11.003_bb0205","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","article-title":"Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"4 Suppl. 78","key":"10.1016\/j.autrev.2017.11.003_bb0210","first-page":"S75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0215","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.20364","article-title":"Predictors of outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis","volume":"50","author":"Mok","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0220","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrneph.2011.150","article-title":"The role of antimalarial agents in the treatment of SLE and lupus nephritis","volume":"7","author":"Lee","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0225","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.autrev.2017.11.003_bb0230","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0272-6386(00)70262-9","article-title":"Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group","volume":"35","author":"Korbet","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0235","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0240","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203310366572","article-title":"Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus","volume":"19","author":"Nossent","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0245","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.autrev.2014.01.055","article-title":"Optimizing outcome in SLE: treating-to-target and definition of treatment goals","volume":"13","author":"Doria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.11.003_bb0250","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2017.11.003_bb0255","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.003_bb0260","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/acr.22774","article-title":"Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period","volume":"68","author":"Medina-Qui\u00f1ones","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.11.003_bb0265","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1191\/096120398678920721","article-title":"Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring","volume":"7","author":"Grande","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0270","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1046\/j.1523-1755.2002.00357.x","article-title":"Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy","volume":"61","author":"Hill","year":"2002","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.autrev.2017.11.003_bb0275","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/ki.1996.528","article-title":"\u201cNephritic flares\u201d are predictors of bad long-term renal outcome in lupus nephritis","volume":"50","author":"Moroni","year":"1996","journal-title":"Kidney Int [Internet]"},{"key":"10.1016\/j.autrev.2017.11.003_bb0280","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2017.11.003_bb0285","first-page":"634","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"50","author":"Griffiths","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.11.003_bb0290","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2017.11.003_bb0295","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.05040513","article-title":"Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis","volume":"9","author":"Parikh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0300","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1046\/j.1523-1755.2002.00280.x","article-title":"Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis","volume":"61","author":"Mosca","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2017.11.003_bb0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0961203314567751","article-title":"Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre","volume":"24","author":"Mahmoud","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.003_bb0310","first-page":"1467","article-title":"Prolonged remission in systemic lupus erythematosus","volume":"32","author":"Urowitz","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0315","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/1529-0131(200112)44:12<2797::AID-ART467>3.0.CO;2-9","article-title":"Systemic lupus erythematosus in three ethnic groups: IX. Differences in damage accrual","volume":"44","author":"Alarcon","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.003_bb0320","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/ker368","article-title":"Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort","volume":"51","author":"Lopez","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.11.003_bb0325","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40620-016-0313-6","article-title":"Remission and withdrawal of therapy in lupus nephritis","volume":"29","author":"Moroni","year":"2016","journal-title":"J Nephrol"},{"key":"10.1016\/j.autrev.2017.11.003_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000173","article-title":"Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey","volume":"4","author":"Ngamjanyaporn","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2017.11.003_bb0335","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2017.11.003_bb0340","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T09:01:31Z","timestamp":1535274091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217302768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1568997217302768"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.11.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}